Current Treatments in Dry Age-Related Macular Degeneration

Dr. Özge Sarıtaş, FEBO

Battalgazi State Hospital, Department of Ophthalmology, Malatya, Türkiye

ABSTRACT

Multifactorial mechanisms, mainly genetic and environmental factors, have been demonstrated in the patho- genesis of dry- type age-related macular degeneration (dAMD). Pathways such as oxidative stress and chron- ic inflammation, including complement activation, which are believed to be significant in pathogenesis, are targeted for newly developed therapies. Currently, many early-phase clinical trials have been concluded pos- itively, and many more are expected to be concluded in the near future. The current treatments for dry AMD will be reviewed in this chapter.

Keywords: Age-related macular degeneration (AMD); Complement inactivating agents; Retina; Geographic atrophy (GA); Neuroprotection

Referanslar

  1. Coleman HR, Chan CC, Ferris FL, 3rd, Chew EY. Age-relat- ed macular degeneration. Lancet. 2008; 372:1835-1845. [Crossref]  [PubMed]
  2. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-re- lated macular degeneration. Lancet.2012; 379:1728-1738. [Crossref]  [PubMed]
  3. Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The complement system and innate immunity. [Link]
  4. Desai D, Dugel PU. Complement cascade inhibition in geo- graphic atrophy: a review. Eye.2022;36(2):294-302. [Crossref]  [PubMed]  [PMC]
  5. Apellis Pharmaceuticals, Inc. Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injec- tions in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration.
  6. Apellis Pharmaceuticals, Inc. A Study to Compare the Effi- cacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Sec- ondary to Age-Related Macular Degeneration.
  7. Wykoff CC, Rosenfeld PJ, Waheed NK, et al. Characterizing new-onset exudation in the Randomized Phase 2 FILLY trial of Complement Inhibitor Pegcetacoplan for Geographic At- rophy. Ophthalmology 2021; 128:1325-1336. [Crossref]  [PubMed]
  8. Steinle NC, Pearce I, Monés J, et al. Impact of baseline char- acteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetaco- plan. Am J Ophthalmol 2021; 227:116-124. [Crossref]  [PubMed]
  9. Efficacy of intravitreal pegcetacoplan in geographic atrophy:24-month results from the phase 3 OAKS and DERBY trials. Accessed July 24, 2023 [Link]
  10. FDA, FDA drug documenters, 2023. Accessed April, 2023 [Link]
  11. Apellis Pharmaceuticals, Inc. An extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL- 2) in subjects with geographic atrophy secondary to AMD (GALE). ClinicalTrials.gov identifier: NCT04770545. Up- dated August 30, 2022
  12. Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacin- captad pegol for geographic atrophy due to age-related mac- ular degeneration. Ophthalmology. 2021; 128:576-586. [Crossref]  [PubMed]
  13. Lueck K, Wasmuth S, Williams J, et al. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye (Lond). 2011; 25:1074-1082. [Crossref]  [PubMed]  [PMC]
  14. Complement modulation reverses pathology in Y402H-ret- inal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function -Cerniauskas- 2020 - STEM CELLS Translational Medicine [Crossref]
  15. Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023; 402:1449-1458. [Crossref]  [PubMed]
  16. Patel SS, Lally DR, Hsu J, et al. Avacincaptad pegol for geo- graphic atrophy secondary to age-related macular degenera- tion: 18-month findings from the GATHER1 trial.Eye. 2023; 37:3551-3557 [Crossref]  [PubMed]  [PMC]
  17. Desai D, Dugel PU. Complement cascade inhibition in geo-graphic atrophy: a review. Eye (Lond). 2022; 36:294-302. Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geo-graphic atrophy due to age-related macular degeneration. Ophthalmology. 2021; 128:576-586. [Crossref]
  18. IVERIC bio, Inc. A phase 3 safety and efficacy study of intra- vitreal administration of Zimura (complement C5 inhibitor). ClinicalTrials.gov identifier: NCT04435366. Updated Sep- tember 28, 2022. [Link]
  19. Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy.Accessed August, 2023 [Link]
  20. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gre- gori G, Penha FM, Moshfeghi AA, Zhang K, Sadda S, Feuer W, Rosenfeld PJ. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the complete study. Ophthalmology. 2014; 121:693-701 [Crossref]  [PubMed]  [PMC]
  21. Alexion Pharmaceuticals. A Phase 2, Double-Masked, Pla- cebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). [Link]
  22. Gange WS, Sisk RA, Besirli CG. Perifoveal chorioreti- nal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated leber congenital amaurosis. Ophthalmol Retina. 2022;6(1):58-64 [Crossref]  [PubMed]  [PMC]
  23. Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Sale- hi- Had H, Dang W, Lin C, Mitra D, Zhu D, Thomas BB, Hikita ST, Pennington BO, Johnson LW, Clegg DO, Hin- ton DR, Humayun MS. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degener- ation. Sci Transl Med. 2018;10: eaao4097. [Crossref]  [PubMed]
  24. Weiss J. Bone marrow derived stem cell ophthalmology treat- ment study II. ClinicalTrials.gov identifier: NCT03011541. Updated August 3, 2022.
  25. Ellis S, Buchberger A, Holder J, Hughes J. GT005, a gene therapy for the treatment of dry age-related macular degen- eration (AMD). Invest Ophthalmol Vis Sci. 2020; 61:2295. [Link]
  26. Cashman SM, Gracias J, Adhi M, Kumar-Singh R. Adeno- virus-mediated delivery of factor H attenuates complement C3 induced pathology in the murine retina: a potential gene therapy for age-related macular degeneration. J Gene Med. 2015; 17:229-243. [Crossref]  [PubMed]
  27. Guymer RH, Wu Z, Hodgson LAB, Laser Intervention in Early Stages of Age-Related Macular Degeneration Study Group et al. Subthreshold nano-second laser intervention in age-related macular degeneration: the lead randomized con- trolled clinical trial. Ophthalmology. 2019; 126:829-838. [Crossref]  [PubMed]
  28. Markowitz SN, Devenyi RG, Munk MR, Croissant CL, Ted- ford SE, Rückert R, Walker MG, Patino BE, Chen L, Nido M, Tedford CE. A double-masked, randomized, sham-con- trolled, single-center study with photobiomodulation for the treatment of dry age related macular de- generation. Retina. 2020; 40:1471-1482. [Crossref]  [PubMed]  [PMC]
  29. Allegro Ophthalmics LLC. A Randomized Controlled, Double Masked, Crossover Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy Of 1.0 Mg Luminate®(Alg-1001) As A Treatment for Non-Exudative Macular Degeneration.
  30. Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014; 132:142-149. [Crossref]
  31. Saad L. A Phase 2/3 Multicenter, Randomized, Double masked, Parallel-group, Placebo-controlled Study to Investi- gate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-relat- ed Macular Degeneration.
  32. GlobeNewswire. Galimedix therapeutics presents data showing safety, tolerability and potential for efficacy of its investigational eyedrops containing GAL-101 at glaucoma 360 conference, 2019
  33. Stealth Bio Therapeutics. Stealth biotherapeutics announces positive results for elamipretide in ophthalmic conditions, 2019. [Link]
  34. Pixium Vision SA. Feasibility Study of Compensation for Blindness with the PRIMA System in Patients with Dry Age-Related Macular Degeneration.
  35. Hudson HL, Lane SS, Heier JS, et al. Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year re- sults. Ophthalmology. 2006;113: 1987-2001. [Crossref]  [PubMed]
  36. Lylyk I, Bleise C, Lylyk PN, et al. Ophthalmic artery an- gioplasty for age-related macular degeneration. J Neu- rointerv Surg.2022; 14:968-972. [Crossref]  [PubMed]  [PMC]